Kymera Therapeutics Inc (KYMR) - News Archive

Showing 4 of 24 results.

Kymera Therapeutics Raises the Bar with Proposed Public Offering to Advance Targeted Protein Degradation Medicines

Kymera Therapeutics Announces Proposed Public Offering to Advance Targeted Protein Degradation MedicinesWATERTOWN, Mass., Jan. 04, 2024 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a pioneering clinical-stage biopharmace...

Jan 4, 2024 Financing Agreement

Revolutionizing Cancer Treatment: Kymera Therapeutics Unveils Encouraging Results of STAT3 Degrader KT-333 Against Stubborn Tumors

Kymera Therapeutics Presents STAT3 Degrader KT-333 at ASH: Early Promising Results Highlight Potential Against a Wide Range of TumorsKymera Therapeutics recently unveiled the interim findings from their Phase 1 clinical...

Dec 11, 2023 • Biotechnology & Pharmaceuticals Industry Clinical Study

Kymera Therapeutics' Breakthrough IRAK4 Degrader Receives $15 Million Boost in Atopic Dermatitis Clinical Trial, Marking a Milestone for the Company

Kymera Therapeutics, a leading biotechnology company focused on advancing breakthrough therapies for immune-mediated diseases, has recently announced a significant milestone in their Atopic Dermatitis (AD) clinical tria...

Dec 7, 2023 Clinical Study

Kymera Therapeutics' KT-474 Shows Promising Phase 1 Results while Revenue Declines - Balancing Efforts for Innovation and Financial Stability

Kymera Therapeutics Reports Positive Phase 1 Trial Results for KT-474 and Decline in RevenuesIn a recent publication featured in Nature Medicine, Kymera Therapeutics announced the encouraging results from the Phase 1 cl...

Nov 13, 2023 Product Service News